Mastercard and Xsolla Level Up the Gaming Experience With Pay With Points in Poland
11.12.2024 10:00:00 CET | Business Wire | Press release
Powered By Mastercard’s Redemptions Solutions, Xsolla Pay With Points Will Be Available For Alior Bank Mastercard Cardholders
Xsolla, a global video game commerce company, and Mastercard are bringing their partnership to Poland for the first time through Alior Bank. Mastercard cardholders with Alior Bank can now use Xsolla Pay with Points to redeem their loyalty points for in-game purchases directly in Xsolla’s Pay Station. Enabled by Mastercard’s digital redemptions capabilities, this integration will allow gamers to pay with loyalty points in a simple and secure way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211317259/en/

(Graphic: Xsolla)
The gaming industry is growing rapidly, with the global number of gamers reaching new heights year after year. However, in-game payments remain an area with room for improvement. Over 40% of consumers report needing assistance with purchasing in-game currency, and over 30% feel that making purchases in online games involves too many steps.1
Xsolla Pay with Points helps solve that problem with a seamless solution that’s fully integrated into the customized Xsolla Pay Station checkout. Using credit card loyalty points earned from everyday spending, Mastercard cardholders with Alior Bank can buy their favorite games, in-game items, and virtual currencies without leaving the gaming platform. Now, when a gamer in Poland wants to make a purchase online for their game using their Mastercard as the form of payment, the points can be redeemed through a simple and user-friendly check-out with fewer clicks and greater confidence.
Hear from the teams
“This collaboration with Alior Bank and Mastercard represents a significant innovation in connecting financial services with gaming. By allowing players to use loyalty points for in-game purchases, we’re creating a seamless and rewarding experience that adds value to everyday transactions and the gaming industry,” said Anton Zelenin, Chief Product Officer, Fintech, Xsolla.
“Working with Mastercard and Alior Bank on the Pay with Points Solution allows us to offer players a simple, safe, and secure way to use loyalty points directly in their favorite games. Consumers can now use those earned points from everyday transactions to mark in-game purchases for digital items and virtual goods to level up their gaming experience,” said Berkley Egenes, Chief Marketing & Growth Officer at Xsolla. “Our goal is to provide equal access and opportunity to everyone, and this integration in Poland demonstrates what is possible for players and developers worldwide.”
Commenting on the launch Scott Abrahams, executive vice president, Global Partnerships, at Mastercard said, “Mastercard embeds technologies and solutions into everyday activities to enhance consumer experiences, and our loyalty redemptions capabilities are just one great example. Our work with Xsolla and Alior Bank demonstrates the industry collaboration that we are driving across the gaming ecosystem globally to enable secure and simple payments and deliver added value that supports people's passions.”
“This solution is another step in building valuable experiences that combine pleasure with everyday benefits. Games play an essential role in the lives of many of our customers, which is why we are happy to support their passion by offering a new way of using loyalty points. Thanks to it, they can develop games during everyday activities, such as shopping,” says Mateusz Tomczak, Product Development Manager at Alior Bank.
To learn about Pay with Points with Xsolla, visit xsolla.pro/pwp1. You can find more details about Mastercard’s digital redemptions solutions here.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world, Xsolla supports leading gaming partners such as Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, among others. For additional information and to learn more, please visit xsolla.com
About Mastercard
Mastercard powers economies and empowers people in 200+ countries and territories worldwide. Together with our customers, we’re building a sustainable economy where everyone can prosper. We support a wide range of digital payments choices, making transactions secure, simple, smart and accessible. Our technology and innovation, partnerships and networks combine to deliver a unique set of products and services that help people, businesses and governments realize their greatest potential. www.mastercard.com
About Alior Bank
Alior Bank is one of the fastest growing full-service banks in Poland. It started operating in 2008 as a new type of bank that combines traditional banking with innovative products. It employs over 7,000 people. The products and services offered by Alior Bank, as well as the quality of its service, have enabled it to attract more than 4.5 million customers. The bank caters for both individual and corporate customers, serving them online and through its 176 branches and 336 partner facilities. www.aliorbank.pl
1 Mastercard Proprietary Gamer Profile & Payments Attitudes Study, Q1 2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211317259/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom